EGFR and lung carcinoma: As a recent example, driver mutations in ctDNA (EGFR, KRAS, or BRAF) and serum concentrations of Cyfra21-1, and possibly CA125, have been described as relevant useful biomarkers for therapy response monitoring and early detection of progression during therapy in lung cancer [162].